Table 2. GvHD after allogeneic SCT,... | American Society of Hematology

Table 2.

GvHD after allogeneic SCT, after prior DLI, and after thalidomide plus DLI

	GvHD after allotransplantation	GvHD after prior DLI	GvHD after thalidomide plus DLI
No.	18	12	18
aGvHD I-IV, %	61	42	11
aGvHD II-IV, %	28	25	None
Limited cGvHD, %	33	33	38^*
Extensive cGvHD, %	6	None	None

	GvHD after allotransplantation	GvHD after prior DLI	GvHD after thalidomide plus DLI
No.	18	12	18
aGvHD I-IV, %	61	42	11
aGvHD II-IV, %	28	25	None
Limited cGvHD, %	33	33	38^*
Extensive cGvHD, %	6	None	None

Four of 6 entered the trial with limited cGvHD without aggravation; 2 of 6 (13%) de novo limited cGVHD; of 18 patients included in the study, only 16 were evaluable for cGVHD.

View Large

This Feature Is Available To Subscribers Only